Top Stories News

The two companies have entered into a three-year programme on the development of early preclinical stage drug candidates.

Pharmexcil hopes to get IJPA's assistance in getting appropriate inputs on regulatory requirements and market dynamics in Japan.

AstraZeneca is acquiring San Diego-based Ardea for $32 per share.

An ABPI report has highlighted the importance of partnerships between universities and pharmaceutical companies and called for greater collaboration to maintain the UK's leadership in medical research.

XTL Biopharmaceuticals, a public company traded on the Tel Aviv Stock Exchange, has announced that it has signed a non-binding letter of intent to acquire a drug development company.

An innovative new solution could help to tackle the major problem of medication non-adherence.

Takeda is enhancing its gout treatment portfolio with the acquisition of URL Pharma.

GE Healthcare and Clino Ltd have announced a joint research project with a view to developing new diagnostic solutions for Alzheimer's disease.

AMRI’s role will initially involve the development and manufacture of the active pharmaceutical ingredient for use in clinical trials.

KAI Pharmaceuticals is to become a wholly owned subsidiary of Amgen.

Abbot's biologic therapy Humira has now received EU approval for the treatment of adult patients with ulcerative colitis.

Shire has revealed that it does not plan to pursue a regulatory filing for MMX mesalamine in patients with a history of diverticulitis, after the drug failed to meet the primary endpoint in a recent phase-III study.

Efficacy and safety data that supported the US FDA's expanded indication for Zostavax in 2011 have been published in Clinical Infectious Diseases.

The companies will combine their expertise to provide a range of services to address pipeline challenges with BCS Class II and IV poorly bioavailable compounds.

Richard Ridinger has been named chief executive officer of Lonza and will take over the role on May 1.

The cooperation combines Charles River’s preclinical oncology study expertise with Metabolon’s analysis of metabolic data to identify both mechanism of action and biomarkers.

The two firms will collaborate to help biopharma companies take advantage of pharmacogenetic solutions, including novel biomarker and assay development services.

Sinovac Biotech has announced the appointment of Mr. Meng Mei as an independent director. The appointment enables Sinovac to comply with NASDAQ Listing Rule 5605 requirement.

Almac has entered into an agreement with Affymetrix for Xcel Array distribution.

SCM Pharma was named the winner of the Science & Technology Award at the North East Business Award for the UK’s Northumberland and Tyneside region.

Seaside Therapeutics has obtained a US patent covering its lead product candidate STX209 for the improvement of social and communication functions in autism spectrum disorders.

Scientists from Tsinghua University will work with Bayer scientists to solve the 3D protein structure of biological molecular targets as a basis for new drug discovery projects.

The two firms have signed a multi-product deal for the development, supply and distribution of alternative dosage form products.

Novasep will expand purification process solutions for biopharmaceuticals including recombinant proteins, peptides and biosimilars, including monoclonal antibodies and insulin, and pharmaceuticals such as optical isomers and certain anti-cancer APIs.

The hostile approach, which is valued at approximately $5.7bn, will now give shareholders until April 20 to accept an offer of $44.50 per share.

The new slogan 'Passion for Innovation. Compassion for Patients.' will be rolled from April 1, 2012 via corporate advertisements, corporate websites and so on.

The acquisition of RuiYi allows Anaphore to access the substantial scientific expertise, capital and potential new collaboration opportunities in the Chinese pharmaceutical marketplace.

Ablynx has extended nanobody alliance with Boehringer Ingelheim.

UCB will fund the collaboration with ?3.6 million over three years to develop medicines that will treat serious diseases in immunology and neurology.

The name for its new research-based pharmaceutical company is derived from a combination of Abbott and 'vie,' which references the Latin root 'vi' meaning life.

The company stated that it decided to withdraw the application based on the CHMP's view that the data provided do not allow the Committee to conclude on a positive benefit-risk balance.

The new expansion in the European, Middle Eastern and African markets is part of the company's plan to have a presence in the top 20 pharmaceutical market regions by 2015.

Heptares will receive an upfront option grant and exercise payments and is eligible to receive future development and commercial milestone payments of as much as $190 million, plus royalties on sales.

The stem cell therapy SB623 is derived from adult bone marrow and has shown safety and efficacy in rodent models of chronic stroke.

It usually takes around six months to complete an assessment and approve a drug for use in Canada. However, Health Canada is speeding up its drug review process to ease the drug shortage.

The new facility will provide localized packaging, analytical services and quality control for high-quality products to support the Company's research and industrial customers in the region.

The move comes as the company is forced to contend with European health spending cuts and generic competition to Plavix, the top-selling blood thinner, which is manufactured at the site.

Sales of Bayer HealthCare are expected to reach approximately EUR 20 billion in 2014, while Bayer CropScience aims to raise sales to more than EUR 8 billion.

UBM has announced that CPHI Worldwide, ICSE, P-MEC Europe and InnoPack will return to Frankfurt, Germany from 22nd to 24th October 2013. The events will run this year from 9th to 11th October in Madrid and had a record breaking year at the Messe Frankf...

Biocon and Pfizer have ended their biosimilar insulin alliance. All rights licensed to Pfizer will now be transferred back to Biocon.

DSM Pharmaceutical Products and Agennix AG have signed a new contract under which DSM will manufacture the oral Dendritic Cell Mediated Immunotherapy talactoferrin for Agennix at commercial levels.

Dr. Colin Minchom will serve as vice president of Hovione's Particle Design Business Unit.

Particle Sciences will offer the technology to clients looking to increase bioavailability or develop parenteral formulations of difficult-to-solubilize compounds.

During the visit to China from February 11 to 22, the team of the CDSCO inspected three API units and one diagnostics units.

Apprenticeships will last between 2–4 years depending on the discipline. All roles will be a combination of on-the-job training and studying.

The report from GBI Research examines the global antifungal therapies, treatment usage patterns and treatment flow algorithm. It also analyzes the geographical distribution of antifungal therapies across the US, the top five countries in the European r...

The leading contract research outsourcing provider's fourth-quarter 2011 net revenues increased 22.5% year over year to $108.5 million.

As the largest pharma ingredients event in the country, CPHI Japan provides an invaluable opportunity to meet in person and continue to build relationships, whether existing or new.

SK Biopharmaceuticals announced that Christopher Gallen, M.D., Ph.D., has joined the company as its new CEO as of March 1.

The acquisition of Xcellerex will allow GE Healthcare to expand its offering of products and services for the manufacture of biopharmaceuticals such as recombinant proteins, antibodies and vaccines.

Dong-A authorizes the exclusive right of DA-1229 to Luye which will be responsible for self-development, reporting and sales of the product’s raw materials and preparation in China.

Canada's Medicago and Osaka-based Mitsubishi Tanabe Pharma have formed a strategic alliance to develop three new rotavirus vaccines.

Prometrika has selected Medidata Solutions as a strategic partner to increase sponsor access to its range of clinical research services.

Catalent Pharma Solutions has completed its acquisition of R.P. Scherer Eberbach, gaining the remaining 49% interest from Gelita AG.

Thrombotech Ltd. has received an IND approval from the FDA enabling the initiation of a Phase IIa clinical trial in the U.S.

The JV will supply globally recommended vaccines in Japan, including Human Papillomavirus (HPV) vaccine, Rotavirus, Seasonal flu, Mumps, Diphtheria Pertussis (DTP), and Measles Rubella (MR) vaccines.

Abbott Laboratories has made a development agreement with Galapagos for a mid-stage rheumatoid arthritis medication.

The partnership will work on the creation of new compounds capable of restoring function in the central nervous system.

The site will manufacture the Ming Che series of tailor-made lab water purification systems and consumables, which will be sold exclusively in China.

The alliance will offer access to all of the services required to perform early assessment of the viability of a potential biosimilar product before initiating multi-center comparator studies in the target patient populations.

Sanofi and the Institut Pasteur has announced the creation of the Sanofi-Institut Pasteur Awards to encourage scientific excellence in the service of health.

Penn Pharma will invest $22 million in its UK facility to strengthen its manufacturing capabilities.

The collaboration will combine Angiochem's expertise in creating novel therapeutics that cross the blood-brain barrier (BBB) with the scientific, development and commercialization capability of GSK in rare diseases.

The alliance aims to boost the efficiency, quality and monitoring of the supply chain processes as part of a continuous optimization process, as well as increase economic efficiency through the reduction of reject quantities.

California-based Alacer is well-known among health-conscious consumers as a provider of Vitamin C supplement products. It produces almost 500 million packets of Emergen-C annually.

Quintiles is extending its footprint in Russia by teaming up with a Russian-based investment firm.

Hospira has announced its membership of the Generic Pharmaceutical Association (GPhA).

BASF posted the fourth-quarter results last Friday and reported a record increase in sales which rose to €73.5bn in 2011.

The planned efficiency measures are part of the Group’s comprehensive transformation program.

Lanthio Pharma has granted Tarix Pharmaceuticals an exclusive license to its lanthionine-stabilized Angiotensin-(1-7) agonistic peptide for the treatment of acute lung injury.

Actelion will pay Auxilium $10 million upfront and will also make up to $16 million in potential regulatory, pricing, and reimbursement milestone payments and $42.5 million in potential sales milestone payments.

Dako announced a new collaboration agreement with Amgen on the development of a diagnostic test for an Amgen cancer drug candidate in clinical development.

Cadila Pharmaceuticals will sell the entire line of Bactiguard?s products throughout India.

Xencor and Boehringer Ingelheim have entered into a new alliance on the development of new biosuperior monoclonal antibodies.

Novartis will be responsible for all costs associated with the development, manufacture and commercialization of EDP-239 and will fund Enanta's drug discovery efforts on certain additional compounds targeting NS5A.

Sigma Life Science has acquired a worldwide license to use Kyoto University's induced pluripotent stem (iPS) cell patent portfolio.

Mr. Gorsky succeeds Bill Weldon, who has served as Chairman and CEO of Johnson & Johnson since 2002.

Dr. Bhatia will lead the research and pharmaceutical development group and oversee DPT's Center of Excellence for R&D in San Antonio.

The German chemicals distributor's new head office will provide room for the firm’s planned growth in India over the next few years.

Pfizer is said to raise about $3bn this year through a part-flotation of its animal health division.

UK’s independent chemical manufacturer Robinson Brothers Limited announced a significant rise in group sales for 2011.

Under the agreement Endeavour will act as the sole scale-up partner for the AKL range of building blocks and chemical intermediates, many of which are commercially novel.

Par Pharmaceutical has completed the acquisition of India-based Edict Pharmaceuticals, a developer and manufacturer of generic pharmaceuticals with 11 ANDAs filed with the FDA.

Under the alliance, Evotec will offer fully integrated respiratory and inflammation focused drug discovery programs, from target to nomination of preclinical development candidates.

The conventional tablets were launched in Germany, France, Italy, Spain, the UK, Denmark, Sweden and Austria this week.

The decision to withdraw the application was based on the CHMP’s assessment that the lack of an active-controlled trial hampers the proper assessment of the benefit-risk balance in European patients in the applied indication.

The BARDA contract includes preclinical efficacy and toxicology studies, clinical studies, manufacturing, and associated regulatory activities for TP-434.

The acquisition will leverage SAFC’s industrial media presence and BioReliance’s biological testing services.

Endeavour Speciality Chemicals has announced the introduction of a line of commercially novel pyridinyl thioureas to be used as building blocks in the research of treatments for prion diseases.

In addition to recommending new user fees to support the review of generic drugs and biosimilars, the FDA budget also contains increased funding ($1.7bn) to improve the safety of drugs and other medical products, advance medical countermeasures and fac...

The new JV will market, distribute and sell a portfolio of innovative pharmaceutical and branded generic products from Merck, Cristália and Eurofarma solely in the Brazilian retail sector.

The facility was built to meet an annual demand for commercial projects > 5 MT and will serve to expand Asymchem's capabilities in high volume processing and back-end ingredient and intermediate production.

Biogen Idec will make an upfront cash payment of $75 million and additional contingent value payments of up to $487.5 million based on the achievement of certain development and approval milestones across multiple indications.

This merger offers an enhanced global scale, a depth of oncology-specific therapeutic expertise and new levels of operational excellence.

Bristol-Myers Squibb has announced the successful completion of the tender offer by Bristol-Myers Squibb Company for all of the outstanding shares of common stock of Inhibitex, Inc.

Under the agreement, the two companies will leverage each other’s strengths to provide a start to finish contract solution for those looking to develop and market hormone eluting devices.

Bosch Packaging Technology is to acquire Eisai’s machinery business to strengthen its position in the pharmaceutical market.

Total revenue for the full-year 2011 increased by 19% to $1,068.1 million, from $895.6 million for the full-year 2010.

This technology is designed to improve the bioavailability of compounds with low aqueous solubility and has been applied to hundreds of compounds at various stages of development.

Promega Corporation says its new assay is more flexible than alternatives.

The new facilities expand on the company’s existing clinical logistics infrastructure throughout North America, Latin America, Europe, Africa and the Asia/Pacific region.

Illumina's Board of Directors determined that the $44.50 per share cash offer is grossly inadequate in multiple respects, dramatically undervalues Illumina and is contrary to the best interests of Illumina's stockholders.

The underlying pharmaceuticals growth came from new products, partly offset by generic competition to older products in the US and Europe and the increased impact of European austerity measures.

Merck will obtain co-development and exclusive global commercialisation rights, whilst Threshold will retain the option to co-commercialise TH-302 in the US.

GlaxoSmithKline will invest A$60m to expand its manufacturing and new drug development activities in Australia.

UK's Melbourn Scientific has appointed laboratory manager, Derek Solomon, as operations director.

Syntagon announced that George K?llner, a Quality Assurance expert, has joined the company.

RohnerChem and evocatal have announced partnership for enzymatic chemistry development and upscaling.

OctoPlus N.V. has signed a formulation development and manufacturing contract with Ferring Pharmaceuticals.

SCM Pharma is to develop and manufacture an injectable neonatal product for BrePco BioPharma.

Catalent Pharma Solutions announces the completion of the expansion of its facility in Aprilia, Italy.

The services include professional study design to sample processing and expert data analysis for DNA and RNA samples.

The alliance offers regional and international sponsors with access to quality clinical trial services throughout Asia.

Amylin's Bydureon diabetes drug has won approval from US regulators.

This is the first time that NIH is leveraging its HIV/AIDS clinical trial networks to advance a tuberculosis vaccine candidate.

India and Japan are likely to sign a protocol to boost their pharmaceuticals trade.

In line with DSM and Indoco's strategy, the agreement represents a step to forge an alliance to expand presence in markets across the globe.

Valeant Pharmaceuticals announced Monday that the company has withdrawn its offer to acquire ISTA Pharmaceuticals.

This joint development project proactively responds to the current market demand for more effective connectivity between equipment from different suppliers to enable development of efficient, streamlined systems.

Encap Drug Delivery has announced the addition of a further pharmaceutical product to its portfolio of commercial products.